Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis

Satoshi Mizutani, Hitoshi Kodera, Yoshiko Sato, Toshihiro Nanki, Shunji Yoshida, Hidekata Yasuoka

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Objectives: Iguratimod (IGU) is a conventional synthetic disease-modifying drug that has been approved based on its additive effects with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). The objective of the study is to establish the effectiveness of IGU with versus IGU without MTX irrespective of whether MTX is well tolerated or not by the patients. Methods: Disease activity scores in 177 RA patients treated using IGU were retrospectively evaluated at baseline and after 4, 12, and 24 weeks, and adverse events (AEs) were noted. Results: IGU reduced the disease activity parameters, disease activity score (DAS)-ESR, DAS-CRP, the simplified disease activity index (SDAI), and clinical disease activity index (CDAI) in the concomitant MTX and non-MTX, female and male, and young and elderly patient groups after 24 weeks. Multivariate analysis demonstrated that IGU was more effective with concomitant MTX and in elderly and male patients. Severe AEs were observed only in the elderly group: two cases of pneumonia, 1 of pneumocystis pneumonia, 1 of heart failure, and 1 of salivary gland adenoma. Conclusions: IGU is effective for RA, especially with concomitant MTX, and in elderly and male patients.

Original languageEnglish
Pages (from-to)123-132
Number of pages10
JournalClinical Rheumatology
Issue number1
Publication statusPublished - 01-2021

All Science Journal Classification (ASJC) codes

  • Rheumatology


Dive into the research topics of 'Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this